Ajanta Pharma Ltd Q1 FY2026 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/8zcygmbzusvt2f6epq1d6hy2.pdf

Key Takeaways


India Branded Formulations

Arvind Agrawal: "I think it is a small way of competition, which is increasing, but I think we already started working on it, and we should be able to certainly come back to our normal IPM growth. So, we will come back on that. It's just that it is a time lag, maybe in another 2, 3 quarters, you will start seeing the improvement."

US Generics

Yogesh Agrawal: "We have some products which are limited competition products, and we believe that the visibility which we have, they should remain like that for the whole current year. We don't expect any addition in that limited competition products. So, we feel comfortable giving the guidance that the current run rate should continue for the rest of the 3 quarters."

Asia & Africa Branded Generics

Yogesh Agrawal: "If you take a blended 2-year growth, it will still be in excess of 16%, 17% growth. So, actually, there is no such correction which is required. We are doing just fine."

Margins & Cost Structure

Arvind Agrawal: "No, I think we have reached quite peak. From here, we don't expect any further achievement or efficiency in the working capital cycle."

Capital Allocation & Inorganic Strategy

Yogesh Agrawal: "There's no requirement of prioritization in one geography or other. There are all kind of resources that are independent on each of the geographies, and they perform independently. There is no constraint on the resources for each of the geographies."

Guidance & Commitments

CommitmentSpecificsTimeline
US Generics revenue run rateCurrent quarterly run rate to sustainRemaining 3 quarters of FY26
US Generics launches2 to 3 more launchesFY26
US ANDA filingsAround 10 filings, plus/minus 1 or 2FY26
India business growth20-25% higher than IPM growth rateFY26
India cardiology recoveryMatch IPM growth2-3 quarters
Asia branded generics growthMid-teens growthFY26
Africa branded generics growthMid- to high single-digit growthFY26
Trade generics growthAround 10% growthFY26
Gross marginAround 78%, plus/minus 1%FY26
R&D spend5% of revenueFY26
EBITDA margin27%, plus/minus 1%FY26
EBITDA margin expansionExpansion expected as expense increases are absorbedFY27
CapExRs. 300 croresFY26
Income tax rateAround 23%FY26
Emerging markets MR headcountAdd ~250 people (~10% increase to ~2,250)FY26
India MR additions~150 total (70 added in Q1, ~80 more)FY26
New therapy review (nephrology, gynecology)Performance reviewYear-end FY26

Key Metrics

MetricQ1 FY26
Revenue from operations₹1,303 cr, +14% YoY
Gross margin79%, +200 bps YoY; includes ~1% one-off benefit from returns provisioning
EBITDA₹351 cr, +6% YoY
EBITDA margin27%, vs 29% YoY
EBITDA (excl. MTM forex loss)₹376 cr, +14% YoY; margin 29%
PAT₹255 cr, +4% YoY
PAT margin20%, vs 21% YoY
PAT (excl. MTM forex loss)+12% YoY; margin 21%
India business revenue₹409 cr, +16% YoY
India branded growth vs IPM10% vs 8% IPM, as per IQVIA MAT June 2025
US Generics revenue₹310 cr, +36% YoY
Asia branded revenue₹304 cr, +10% YoY
Africa branded revenue₹228 cr, -1% YoY; flat in local currency
Africa Institution revenue₹38 cr, -8% YoY
R&D spend4% of revenue; ₹56 cr vs ₹51 cr YoY
Other expenses₹373 cr, +42% YoY; includes ₹25 cr MTM forex loss
Cash flow from operations₹282 cr; cash conversion ratio 80%
Free cash flow₹209 cr; FCF to PAT conversion 82%
ROCE33% at end of June 2025
RONW26% at end of June 2025
CapEx₹72 cr in Q1; full-year guidance ₹300 cr
India MR additions70 added in Q1; ~150 expected for full year (total additions for the year)
Emerging markets MR additions40 added in Q1; ~250 expected for full year